Clinical Trial Update: Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of palbociclib in molecularly characterized ER-positive/HER2-negative metastatic breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-02-26